I read an article this week featuring Prof D of the Institute for Cancer Vaccines and Immunotherapy. He has been trialling the use of IMM 101 for melanoma with great success since 2006. I took interest because the article mentioned that Avastin had been trialled for melanoma, having been promising for breast and bowel cancer. It wasn't successful but I recalled an "off-label" use of this drug for a central venous occlusion I had a few years back. Three injections of the stuff into my left eyeball gave me back 90% of my sight in that eye. So, though not actually approved for that use, it was known to be safe and could therefore be used.
Now, I am undergoing immunotherapy for bladder cancer, which will with luck also deal with my PCa, for which use it is not yet approved by NICE. Now both these cancers, like bowel cancer and breast cancer and melanoma are "solid cancers" and it is becoming clear that immunotheray treatments for one may be beneficial for all of them. Yet the approval mechanism through NICE is incredibly long-winded, largely because these drugs are pretty expensive.
IMM 101 on the other hand is not, as it is actually stuff originally developed for treating TB. It is based on heat killed bugs and is simply injected into the skin, once a month, to stimulate the immune system.
Can anyone suggest why an inexpensive safe drug should not be used "off label" without further ado? Prof D thinks it could perhaps be used as standard with a checkpoint inhibitor like Keytruda, which is alas expensive to give an immunotherapy double whammy. I shall talk to my oncologist about IMM 101 next week, but he is a cautious fellow and I don't have great hopes of a Eureka moment with him, but maybe more adventurous oncologists elsewhere could take a leap of faith?
Food For Thought?
AC